Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel D Banister

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Handbook of Experimental Pharmacology|July 8, 2018
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: OriginsSamuel D Banister, Mark Connor
Current Pharmaceutical Design|February 1, 2012
The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidenceSamuel D Banister, Michael Kassiou
Handbook of Experimental Pharmacology|August 15, 2018
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: EvolutionSamuel D Banister, Mark Connor
Journal of Labelled Compounds & Radiopharmaceuticals|November 29, 2013
The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET)Samuel D Banister, Miral Manoli, Michael Kassiou
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligandsSamuel D Banister, Louis M Rendina, Michael Kassiou
Current Pharmaceutical Design|January 29, 2016
The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) DiseasesCorinne Beinat, Samuel D Banister, Marco Herrera, et al.
Pharmacological Research|February 21, 2021
Understanding the complex pharmacology of cannabidiol: Mounting evidence suggests a common binding site with cholesterolLewis J Martin, Samuel D Banister, Michael T Bowen
ACS Chemical Neuroscience|June 3, 2017
Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACAMitchell Longworth, Mark Connor, Samuel D Banister, et al.
Biochemical Pharmacology|September 1, 2019
Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonistsElise Wouters, Jolien Walraed, Samuel D Banister, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
11-{[2-(3-Fluoro-phen-yl)eth-yl](meth-yl)amino}-penta-cyclo-[5.4.0.0.0.0]undecan-8-oneSamuel D Banister, Jack K Clegg, Raphy Hanani, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Handbook of Experimental Pharmacology|July 8, 2018
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: OriginsSamuel D Banister, Mark Connor
Current Pharmaceutical Design|February 1, 2012
The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidenceSamuel D Banister, Michael Kassiou
Handbook of Experimental Pharmacology|August 15, 2018
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: EvolutionSamuel D Banister, Mark Connor
Journal of Labelled Compounds & Radiopharmaceuticals|November 29, 2013
The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET)Samuel D Banister, Miral Manoli, Michael Kassiou
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligandsSamuel D Banister, Louis M Rendina, Michael Kassiou
Current Pharmaceutical Design|January 29, 2016
The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) DiseasesCorinne Beinat, Samuel D Banister, Marco Herrera, et al.
Pharmacological Research|February 21, 2021
Understanding the complex pharmacology of cannabidiol: Mounting evidence suggests a common binding site with cholesterolLewis J Martin, Samuel D Banister, Michael T Bowen
ACS Chemical Neuroscience|June 3, 2017
Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACAMitchell Longworth, Mark Connor, Samuel D Banister, et al.
Biochemical Pharmacology|September 1, 2019
Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonistsElise Wouters, Jolien Walraed, Samuel D Banister, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
11-{[2-(3-Fluoro-phen-yl)eth-yl](meth-yl)amino}-penta-cyclo-[5.4.0.0.0.0]undecan-8-oneSamuel D Banister, Jack K Clegg, Raphy Hanani, et al.
Pageof 9